Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 9/20 | 0.41 |
| ▸ | KDR | P35968 | 9/20 | 0.34 |
| ▸ | CSF1R | P07333 | 6/20 | 0.34 |
| ▸ | KIT | P10721 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | SIK1 | P57059 | 1/20 | 0.31 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.31 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24231379 | 0.89 | FLT3 (0.45) | FLT3KDRCSF1RKITCYP2D6 | |
| SCHEMBL25991407 | 0.89 | FLT3 (0.45) | FLT3KDRCSF1RKITCYP2D6 | |
| SCHEMBL26358255 | 0.88 | FLT3 (0.43) | FLT3KDRCSF1RKITCYP2D6 | |
| SCHEMBL26358046 | 0.88 | FLT3 (0.54) | FLT3KDRCSF1RKITCYP2D6 | |
| SCHEMBL24231319 | 0.88 | FLT3 (0.49) | FLT3KDRCSF1RKITCYP2D6 | |
| SCHEMBL25989698 | 0.88 | FLT3 (0.49) | FLT3KDRCSF1RKITCYP2D6 | |
| SCHEMBL26358257 | 0.86 | FLT3 (0.43) | FLT3KDRCSF1RKITCYP2D6 | |
| SCHEMBL26357442 | 0.86 | FLT3 (0.54) | FLT3KDRCSF1RKITCYP2D6 | |
| SCHEMBL26358267 | 0.84 | FLT3 (0.39) | FLT3KDRCSF1RKITCYP2D6 | |
| SCHEMBL26358260 | 0.84 | MAPK8 (0.42) | FLT3KDRCSF1RKITCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK2, IRAK3 | FLT3 1/4885KDR 640/4885CSF1R 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.